Contact X-ray Brachytherapy as a Boost Therapy After Neoadjuvant (Chemo)Radiation in High-Risk Locally Advanced Rectal Cancer
High-risk patients with rectal cancer treated with CXB boost had more distant relapses, but comparable locoregional tumor control, organ preservation, disease-free survival, and overall survival to lower risk patients, with acceptable toxicities. CXB boost is, therefore, a viable option for selected high-risk patients with rectal cancer. Timely reassessment, prompt referral, and CXB dose optimization are crucial for improving outcomes.
Authors
- Rajaram Sripadam (ORCID: https://orcid.org/0000-0003-4021-0611)
- Arthur Sun Myint (ORCID: https://orcid.org/0000-0001-5323-5696)
- D. Mark Pritchard (ORCID: https://orcid.org/0000-0001-7971-3561)
- Muneeb Ul Haq (ORCID: https://orcid.org/0000-0002-2303-7469)
- Carrie A. Duckworth (ORCID: https://orcid.org/0000-0001-9992-7540)
- Helen Wong (ORCID: https://orcid.org/0000-0002-2088-8401)
- David M. Hughes (ORCID: https://orcid.org/0000-0002-1287-9994)
- Ngu Wah Than (ORCID: https://orcid.org/0000-0003-4991-5431)
Institutions
- University of Liverpool (GB)
- Clatterbridge Cancer Centre NHS Foundation Trust (GB)
- Molecular Oncology (United States) (US)
Publication Details
- Journal
- International Journal of Radiation Oncology*Biology*Physics
- Published
- 2024-12-13
- DOI
- https://doi.org/10.1016/j.ijrobp.2024.11.113
- Citations
- 1
- Primary Topic
- Colorectal Cancer Surgical Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- Horizon 2020 Framework Programme
- Center for Autonomous Systems and Technologies
- HORIZON EUROPE Marie Sklodowska-Curie Actions